Connect Biopharma (NASDAQ:CNTB) Stock Rating Reaffirmed as “Buy” by Canaccord Genuity Group

by · The Markets Daily

Connect Biopharma (NASDAQ:CNTB – Get Free Report)‘s stock had its “buy” rating reaffirmed by Canaccord Genuity Group in a research note issued to investors on Tuesday, Benzinga reports.

CNTB has been the subject of several other research reports. Wall Street Zen downgraded Connect Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Weiss Ratings cut Connect Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, October 21st. HC Wainwright restated a “buy” rating on shares of Connect Biopharma in a report on Wednesday, October 28th. BTIG Research lowered their target price on Connect Biopharma to $5.00 and set a “buy” rating for the company in a research note on Wednesday, September 30th. Finally, Leerink Partners began coverage on Connect Biopharma in a report on Monday, October 12th. They issued an “outperform” rating and a $4.00 price target for the company. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $5.88.

Check Out Our Latest Analysis on CNTB

Connect Biopharma Price Performance

Shares of NASDAQ:CNTB traded down $0.02 during trading on Tuesday, reaching $0.62. The stock had a trading volume of 367,687 shares, compared to its average volume of 1,355,948. The stock has a market capitalization of $39.36 million, a PE ratio of -0.52 and a beta of 0.06. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.37 and a quick ratio of 2.37. Connect Biopharma has a 52 week low of $0.55 and a 52 week high of $3.82. The business’s 50-day moving average price is $1.02 and its 200 day moving average price is $2.10.

Connect Biopharma (NASDAQ:CNTB – Get Free Report) last released its quarterly earnings results on Monday, November 16th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. The business had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.12 million. As a group, equities analysts predict that Connect Biopharma will post -1.09 earnings per share for the current year.

Institutional Trading of Connect Biopharma

Hedge funds have recently modified their holdings of the stock. BML Capital Management LLC lifted its stake in shares of Connect Biopharma by 574.1% during the third quarter. BML Capital Management LLC now owns 3,864,400 shares of the company’s stock valued at $4,251,000 after acquiring an additional 3,291,113 shares during the period. ADAR1 Capital Management LLC bought a new position in Connect Biopharma in the first quarter valued at about $1,945,000. Knott David M Jr boosted its holdings in Connect Biopharma by 93.9% in the first quarter. Knott David M Jr now owns 387,835 shares of the company’s stock valued at $1,016,000 after acquiring an additional 187,835 shares during the last quarter. Marshall Wace LLP boosted its holdings in Connect Biopharma by 12.0% in the third quarter. Marshall Wace LLP now owns 376,029 shares of the company’s stock valued at $414,000 after acquiring an additional 40,387 shares during the last quarter. Finally, Bank of America Corp DE acquired a new stake in Connect Biopharma in the first quarter worth about $41,000. 58.72% of the stock is owned by institutional investors.

Connect Biopharma Company Profile

(Get Free Report)

Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.

Further Reading